Corporate Governance

The Board recognises its accountability to shareholders and is committed to maintaining high standards of corporate governance.

You can access the terms of reference for our Committees, the latest version of the Articles of Association, information on Directors' shareholdings and Directors' Remuneration Policy here.

Directors' Remuneration Policy

07 June 2020

Remuneration Statement

19 November 2021

Articles of Association

18 October 2019

Board Committees

Audit Committee

Members: Julian Heslop (Chair), Ishbel Macpherson, Dr Lawson Macartney, Lisa Bright and Alison Platt 

Role: The Audit Committee’s key role is to review and report to the Board on financial reporting and internal financial control effectiveness, and to monitor the effectiveness of the external audit process and internal audit function.

December 2020

Disclosure Committee

Members: Ian Page (Chair), Paul Sandland and Melanie Hall

Role: The Disclosure Committee’s key role is to develop and maintain adequate procedures, systems and controls to comply with the Company’s obligations regarding identification and disclosure of inside information.

April 2021

Nomination Committee

Members: Tony Rice (Chair), Julian Heslop, Ishbel Macpherson, Dr Lawson Macartney, Lisa Bright and Alison Platt 

Role: The purpose of the Nomination Committee is to lead the appointment process, satisfy itself that plans are in place for orderly succession for appointments to the Board and Senior management, and oversee the development of a diverse pipeline for succession.

February 2021

Remuneration Committee

Members: Ishbel Macpherson (Chair), Tony Rice, Julian Heslop, Dr Lawson Macartney, Lisa Bright and Alison Platt 

Role: The Remuneration Committee’s key role is to determine remuneration policies, that are designed to support strategy and promote long term sustainable success, and set the remuneration of the Company’s Chairman, Executive Directors and Senior Executive Team.

Our Executive Directors’ pay continues to be implemented in accordance with the Remuneration Policy approved by the shareholders at the 2020 AGM.

June 2021

Directors Shareholding

The beneficial interests of the Directors in office and their families in the share capital of Dechra Pharmaceuticals PLC are as follows:

Director As at 30 November 2021  
  Number of Ordinary Shares Percentage of issued share capital
Tony Rice 20,000 0.018%
Ian Page 358,021 0.330%
Paul Sandland 9,651 0.009%
Tony Griffin 33,463 0.031%
Lisa Bright 788 0.001%
Julian Heslop 6,000 0.006%
Lawson Macartney 5,880 0.005%
Ishbel Macpherson 5,848 0.005%
Alison Platt 1,363 0.001%

Section 172 Statements

The Companies (Miscellaneous Reporting) Regulations 2018 require Dechra Pharmaceuticals PLC and one of its subsidiaries to publish a statement explaining how the Directors have given due regard for the matters set out in section 172 (1) (a) to (f) of the Companies Act 2006 while performing their duty to promote the success of the Company for the benefit of its members as a whole (section 172 statement).

The Group's section 172 statement can be found on the online Annual Report 2020.

Below is the section 172 statement for the Group's subsidiary captured by these Regulations.